The digital health firm Noom has finalised its purchase of Tailor Made Compounding (TMC) in a move that signals a major pivot toward healthy aging and longevity. This deal represents Noom’s largest investment to date and its first significant acquisition. By bringing the licensed 503A pharmacy in-house, the company intends to move beyond its traditional focus on weight loss and hormonal health.
Based in Princeton, New Jersey, Noom plans to integrate TMC’s capabilities to offer prescription-grade wellness interventions at scale. The pharmacy currently operates in 46 states and specialises in both sterile and non-sterile compounding. Its extensive formulary includes peptide-based therapies like sermorelin and healthy aging treatments such as NAD+. Noom intends to combine these clinical catalysts with its established lifestyle and behaviour change platform to improve long-term user outcomes.
Tailor Made Compounding will continue to function as a wholly owned subsidiary under the leadership of its current CEO, Ross Jordan. The pharmacy recently expanded its state-of-the-art facility to over 40,000 square feet. This expansion includes advanced environmental controls and inventory systems designed to meet updated industry standards. TMC currently serves more than 400 clinics and various telehealth providers, a client base it will continue to support following the merger.
Geoff Cook, CEO of Noom, said: “Weight health is the entry point to preventive care—and foundational to healthy aging. But it’s not the end point. This acquisition continues Noom’s expansion into healthy aging, supporting Noom’s mission to empower everyone, everywhere to live better longer—every day. With the acquisition, we plan to broaden our formulary to include peptide-based therapies, like sermorelin, and healthy aging interventions, like NAD+, as we further expand the conditions we serve beyond weight and hormonal health.”
Cook added: “Noom’s trusted brand and proven lifestyle platform drive high engagement, enabling superior outcomes. By pairing sustainable behavior change with prescription-grade catalysts, we make lasting change feel easy. TMC produces those catalysts. By bringing this capability in-house, we’re building the infrastructure to scale proactive care responsibly, grounded in quality, compliance, and long-term outcomes. We have experienced the integrity and rigor of TMC’s leadership team and organization firsthand, and could not be more pleased to bring TMC into the Noom family.”
Ross Jordan, CEO of Tailor Made Compounding, commented: “Tailor Made Compounding was built to deliver the highest-quality therapies to support every individual’s health and wellbeing. By joining Noom, we can integrate those therapies into a proven behavior-change platform focused on long-term outcomes. With medicine and habit science working together, we can support a healthcare ecosystem built for individualized care and lasting outcomes.”
Noom expects the full integration of the pharmacy to be completed later this summer.
